AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$NRIX

Hansen Gwenn sold $37K of NRIX

Hansen Gwenn (Chief Scientific Officer) sold 1,452 shares of Nurix Therapeutics, Inc. (NRIX) at $25.47 on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hansen Gwenn
Published Sep 1, 2026, 9:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NRIX
Neutral
medium confidence
Mentioned
$NRIX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NRIXNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to shift market sentiment for NRIX.

02

Market read

Limited relevance; the filing provides a routine update on insider holdings with minimal trading impact.

03

What to watch

The 10b5‑1 plan indicates pre‑planned execution, reducing the likelihood of insider timing concerns.

Relevance 2/10Novelty 4/10Timing: today

Background

Form 4 filings disclose insider transactions; routine 10b5‑1 sales are common and often pre‑scheduled.

Company-level read

Ticker impact

$NRIXNeutralMedium confidence
Context

Chief Scientific Officer sold 1,452 shares for $36,982 via a 10b5-1 plan, reducing his stake to 117,227 shares.

Expected impact

Potential modest dip of 0.5‑1% if market reacts to the sale.

Evidence & confidence

The sale amount is under $50k and represents a tiny fraction of total holdings; such routine 10b5‑1 sales rarely move price materially.

Market effects

Sector

None; the sale is company‑specific and does not affect the broader biotech sector.

Regional

None; the filing is a US SEC disclosure with no regional ripple.

Global

None; the transaction size is too small to influence global markets.

Counterpoint

What could challenge this read

If the insider had insider knowledge, the sale could foreshadow upcoming negative news, warranting a short‑term watch.

Key entities

  • person
    Hansen Gwenn

    Chief Scientific Officer of Nurix Therapeutics, reporting a sale of 1,452 shares.

  • company
    Nurix Therapeutics, Inc.

    Biotech firm (NASDAQ: NRIX) whose insider transaction is reported.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NRIX insider trading history →

Related articles

Med

Nurix Therapeutics stock is up, what you need to know

Nurix Therapeutics (NRIX) shares rose 3.4% after appointing Dr. Arati V. Rao as chief medical officer. Dr. Rao will oversee clinical development, including the BTK degrader bexobrutideg partnered with Roche. The stock closed at $16.33, up 2.8% from the previous close. Nurix has faced volatility, including a 39.8% drop last week due to Sanofi ending a Phase 1 study. The company has $1.1B in cash, funding operations into 2029.

tradingview.com
$NRIXHighAI 8/10

StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate

Nurix Therapeutics (NRIX) shares fell 38% after Sanofi (SNY) terminated development of a key Phase I immunology candidate, SAR448272 (NX-3911), under their collaboration. Despite this, the rest of the collaboration remains intact, and Nurix maintains a strong cash position. Analysts note Nurix's potential in the oral protein degrader space, particularly its partnership with Roche (RO) for bexobrutideg (NX-5948), which targets a $48B market opportunity across five diseases.

genengnews.com
$NRIXMedAI 8/10

Nurix to present bexobrutideg data at ASH meeting

Nurix Therapeutics (NASDAQ:NRIX) will present Phase 1a/1b study data for bexobrutideg at the ASH meeting in December 2026. The data shows clinical activity and tolerability at 600 mg daily. The drug is being developed with Roche for treating relapsed/refractory CLL and SLL. Nurix is also conducting multiple clinical trials, including Phase 2 and 3 studies.

investing.com